In 2003, the World Health Organization published a landmark report: "Adherence to Long-Term Therapies: Evidence for Action." It was the most comprehensive global assessment of medication adherence ever undertaken. Its central finding was stark: in developed countries, adherence among patients with chronic diseases averages just 50%.
Two decades later, that number hasn't moved. A 2024 review in Frontiers in Pharmacology confirmed that adherence rates remain stubbornly at the 50% mark. Twenty years of digital health innovation, billions of pounds of investment, and thousands of medication apps — and the needle hasn't shifted.
What did the WHO get right? What did they miss? And why have two decades of technology failed to solve a problem we've known about since 2003?
What the WHO Got Right
The Scale Was Accurate
The WHO's estimate of 50% non-adherence for chronic diseases has been validated repeatedly. Studies across conditions — hypertension, diabetes, depression, asthma — consistently show that roughly half of patients don't take their medications as prescribed. The WHO correctly identified this as a global health crisis, not a minor inconvenience.
The Causes Are Multifactorial
The WHO report correctly identified that non-adherence isn't a single problem with a single solution. It categorised five dimensions of non-adherence:
- Socio-economic factors: Cost, health literacy, social support
- Healthcare system factors: Provider-patient relationship, access, follow-up
- Condition-related factors: Symptom visibility, disease progression
- Therapy-related factors: Complexity, side effects, duration
- Patient-related factors: Beliefs, motivation, cognitive capacity
This framework remains the gold standard for understanding non-adherence. No single intervention — not a pill, an app, or a policy — can address all five dimensions. The WHO understood this in 2003.
The Economic Burden Is Enormous
The WHO estimated that non-adherence costs billions globally. Subsequent research has confirmed this. In the UK alone, the economic burden of non-adherence is estimated at £1-9 billion annually when including downstream costs — hospital admissions, disease progression, and lost productivity.
What the WHO Got Wrong
Underestimating the Persistence of the Problem
The 2003 report was implicitly optimistic. It presented evidence-based interventions and suggested that systematic application of these interventions could improve adherence. Twenty years later, the evidence is clear: knowing what works and actually implementing it are very different things. The gap between evidence and implementation has been the story of medication adherence for two decades.
Not Anticipating the App Problem
The WHO report predated the smartphone era. It couldn't have predicted that the primary digital response to non-adherence would be thousands of medication reminder apps that a 2023 review in JMIR Aging described as "glorified alarm clocks."
Most medication apps treat non-adherence as a memory problem. It isn't. It's a behavioural, educational, social, and systemic problem. A notification can solve a memory problem. It can't solve a behavioural one.
The WHO's five dimensions of non-adherence require five different types of intervention. A simple reminder addresses one dimension — patient-related memory failure. It doesn't address health literacy (understanding why food matters), therapy complexity (tracking injections across multiple sites), social support (family awareness of missed doses), or system factors (sharing adherence data with GPs).
Overestimating the Impact of Isolated Interventions
The WHO report catalogued interventions that worked in specific contexts — but many were isolated, single-component interventions. In practice, adherence requires multi-component approaches: reminders plus education plus social support plus simplification. No single intervention is sufficient. This is something the WHO acknowledged in its framework but didn't emphasise enough in its recommendations.
Where We Are Now: 2024
The Frontiers in Pharmacology 2024 review confirmed that adherence rates remain at approximately 50% globally. The review also noted several important developments:
- Digital interventions show promise — but adoption remains low, and most are single-component (reminders only)
- Behavioural interventions (combining reminders with education, feedback, and social support) show better results than reminders alone
- Integrated approaches — where adherence tools connect to the healthcare system — outperform standalone apps
- The app market is saturated with low-quality tools that don't address the root causes of non-adherence
The Gap: Reminder Apps vs. True Adherence Solutions
Most medication apps on the market today address one dimension of non-adherence: memory. They send a notification. The patient remembers (or doesn't). The app logs it (or doesn't). That's the extent of the intervention.
The opportunity — the one DoseStream was built to address — is to build a tool that addresses multiple dimensions simultaneously:
DoseStream's 4-level escalating system addresses the memory dimension with more than a single notification. It re-fires, escalates in urgency, uses distinct vibration patterns, and integrates with care circles for social escalation.
DoseStream's FoodIntelligenceDatabase addresses the education dimension. When patients understand why a medication needs food — not just that it does — adherence improves. The database covers 80+ medications with specific food instructions.
DoseStream's care circle feature addresses the social dimension. Family members can monitor adherence in real time, send nudges, and receive alerts when doses are missed. QR join makes it accessible for non-technical family members.
DoseStream's InjectionSiteTracker addresses the complexity dimension for injectable medications. With 10 tracked sites, 7-day rotation, and body map visualisation, it reduces the cognitive load of managing complex injection regimens.
DoseStream's health reports address the system dimension. Exportable adherence data can be shared with GPs, enabling informed clinical conversations rather than guesswork.
The Opportunity
The gap between what reminder apps do and what adherence solutions need to do is the opportunity. DoseStream was built to close that gap.
The WHO identified the problem in 2003. Twenty years of digital health innovation hasn't solved it — partly because most solutions address only one dimension of a five-dimensional problem. The apps that will move the needle are the ones that address multiple dimensions simultaneously: memory, education, social support, complexity, and system integration.
DoseStream is built on that principle. Not as a glorified alarm clock. As a multi-component adherence platform that happens to live on your phone, cost £8.75, and never sell your data.
The WHO got the diagnosis right in 2003. The treatment plan is still being written. DoseStream is one part of it.